Company & Sponsor Intelligence
TauRx Therapeutics Ltd
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting0
Completed4
Countries1
Therapeutic footprint
alzheimersdementia_other
Indexed studies
NCT03446001Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT01253122Comparative Bioavailability in Healthy Elderly Volunteers
alzheimers · PHASE1
alzheimers · PHASE1
NCT01626378Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
dementia_other · United StatesPHASE3
dementia_other · United StatesPHASE3
NCT02245568Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT00515333TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
alzheimers · PHASE2
alzheimers · PHASE2
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →